EE213 Cost-Effectiveness Analysis of Axicabtagene Ciloleucel, Brexucabtagene Autoleucel, and Standard of Care for Treatment of Relapsed/Refractory Mantle Cell Lymphoma

Abstract

Authors

B Ghanem L Brown E Seoane-Vazquez

Full Text Cite This Article
Back to Volume 25, Supplemental Issue 7S
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×